Advertisement

Pathogenetic studies of motor fluctuations in Parkinson’s disease

  • T. N. Chase
  • M. M. Mouradian
  • G. Fabbrini
  • J. L. Juncos
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Summary

Pharmacokinetic and pharmacodynamic mechanisms for levodopa have been studied in relation to the pathogenesis of the motor fluctuations which complicate advanced Parkinson’s disease. Since levodopa clearance from the general circulation was found to be similar in patients with wearing-off or on-off phenomena and those with a stable response to levodopa, peripheral pharmacokinetic factors are unlikely to be involved. Efficacy half-time for levodopa, on the other hand, was significantly reduced in patients with mainly wearing-off fluctuations in comparison to those manifesting a stable response to oral levodopa; individuals with predominantly on-off phenomenon had an even more extreme reduction in the duration of the antiparkinsonian action of levodopa. Conversion from oral to intravenous levodopa treatment immediately stabilized plasma levodopa levels in both the wearing-off and on-off groups; motor variability also decreased, especially in those with wearing-off phenomenon. During 11 days of continuous intravenous levodopa therapy, additional reductions in motor fluctuations occurred in both groups, but at a significantly faster rate in patients with wearing-off than in those with on-off responses. These results suggest that wearing-off phenomenon may arise as a consequence of the degeneration of dopamine terminals due to natural disease progression with a resultant inability to buffer variations in levodopa availability; on-off phenomenon, may reflect additional postsynaptic dopamine receptor dysregulation, possibly in response to the resultant, nonphysiologic fluctuations in synaptic dopamine.

Keywords

Motor Fluctuation Levodopa Therapy Plasma Levodopa Response Fluctuation Oral Levodopa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barbeau A (1974) The clinical physiology of side effects in long-term L-dopa therapy. Adv Neurol 5: 347–365PubMedGoogle Scholar
  2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455PubMedCrossRefGoogle Scholar
  3. Bunney BS, Walters JR, Roth RH, Aghajanian G (1973) Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560–571PubMedGoogle Scholar
  4. Cadwallader DE (1983) Biopharmaceutics and drug interactions. Raven Press, New York, pp 123–133Google Scholar
  5. Chase TN, Juncos J, Serrati C, Fabbrini G, Bruno G (1986) Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. Adv Neurol 45: 477–480Google Scholar
  6. Chase TN, Juncos JL, Fabbrini G, Mouradian MM (1987) Controlled release levodopa- carbidopa preparations in the treatment of motor response fluctuations in Parkinson’s disease. In: Clifford-Rose F (ed) Parkinson’s disease. J Libby, London, pp 163–167Google Scholar
  7. Doller HJ, Connor JD (1980) Changes in neostriatal dopamine concentrations in response to levodopa infusion. J Neurochem 34: 1264–1269PubMedCrossRefGoogle Scholar
  8. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987 a) 3-0-methyldopa and motor fluctuations in Parkinson’s disease. Neurology 37: 856–859Google Scholar
  9. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987 b) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol 21: 370–376Google Scholar
  10. Fahn S (1980) On-off’ phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441CrossRefGoogle Scholar
  11. Gervas JJ, Murdas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282PubMedCrossRefGoogle Scholar
  12. Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 107: 487–506PubMedCrossRefGoogle Scholar
  13. Hornykiewicz O (1979) Compensatory biochemical changes at the striatal dopamine synapse in Parkinson’s disease - limitations of L-dopa therapy. Adv Neurol 24: 275–281Google Scholar
  14. Juncos JL, Serrati C, Fabbrini G, Chase TN (1985) Fluctuating levodopa concentrations and Parkinson’s disease. Lancet 2: 440PubMedCrossRefGoogle Scholar
  15. Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Kask AM, Chase TN (1987 a) Controlled release levodopa treatment of motor fluctuations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 50: 194–198PubMedCrossRefPubMedCentralGoogle Scholar
  16. Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN (1987 b) Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 44: 1003–1005PubMedCrossRefGoogle Scholar
  17. Juncos JL, Mouradian MM, Fabbrini G, Serrati C, Chase TN (1987 c) Levodopa methyl ester treatment of Parkinson’s disease. Neurology 37: 1242–1245PubMedCrossRefGoogle Scholar
  18. Kartzinel R, Calne DB (1976) Studies with bromocriptine Part 1. On-off’ phenomena. Neurology 26: 508–510CrossRefGoogle Scholar
  19. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61PubMedCrossRefGoogle Scholar
  20. Melamed E, Hefti F, Wurtman RJ (1980) Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8: 558–563PubMedCrossRefGoogle Scholar
  21. Marsden CD, Parkes JD (1976) On-off’ effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292–296PubMedCrossRefGoogle Scholar
  22. Morgan JP, Bianchine JR, Spiegel HE, Rivera-Calimlin L, Hersey RM (1971) Metabolism of levodopa in patients with Parkinson’s disease. Arch Neurol 25: 39–44PubMedCrossRefGoogle Scholar
  23. Mouradian MM, Juncos JL, Fabbrini G, Chase TN (1987) Motor fluctuations in Parkinson’s disease: pathogenetic studies and parenteral levodopa therapy. Ann Neurol 22: 415–419CrossRefGoogle Scholar
  24. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The “on-off” phenomenon in Parkinson’s disease. Relation to the levodopa absorption and transport. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  25. Nutt JG, Woodward WR, Anderson JL (1985) The effect of carbidopa on the pharmacokinetics of intravenous administered levodopa: The mechanism of action in the treatment of parkinsonism. Ann Neurol 18: 537–543PubMedCrossRefGoogle Scholar
  26. Ogasahara S, Nishikawa Y, Yakahashi M, Wade K, Nakamura Y, Yorifuji S, Tarui S (1984) Dopamine metabolism in the central nervous system after discontinuation of L- dopa therapy in patients with Parkinson disease. J Neurol Sci 66: 151–163PubMedCrossRefGoogle Scholar
  27. Papavasiliou PS, McDowell FH, Wang YY, Rosal U, Miller ST (1979) Plasma dopa and growth hormone in parkinsonism: oscillations in symptoms. Neurology 29: 194–200PubMedCrossRefGoogle Scholar
  28. Reches A, Fahn S (1982) 3-0-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271Google Scholar
  29. Rossor MN, Watkins J, Brown MJ, Reid JL, Dollery CT (1980) Plasma levodopa, dopamine and therapeutic response following levodopa therapy of parkinsonian patients. J Neurol Sci 46: 385–392PubMedCrossRefGoogle Scholar
  30. Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with levodopa in Parkinson’s disease. Q J Med 49: 283–293PubMedGoogle Scholar
  31. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148PubMedCrossRefGoogle Scholar
  32. Tolosa ES, Martin WE, Cohen HP, Jacobson RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • T. N. Chase
    • 1
  • M. M. Mouradian
    • 1
  • G. Fabbrini
    • 1
  • J. L. Juncos
    • 1
  1. 1.Experimental Therapeutics BranchNational Institutes of Health/National Institute of Neurological and Communicative Disorders and StrokeBethesdaUSA

Personalised recommendations